Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-TCR055 in Unresectable Hepatocellular Carcinoma
NCT04368182Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Apr 2020
- Primary completion
- Aug 2020
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AFP specific T cell receptor T cells in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Primary endpoint: Safety of C-TCR055 at 12 months. Status: unknown.
02
Drugs
AFP specific T cell receptor T cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04368182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04368182.